DOMA Perpetual Capital Management, owning 6.83% of Pacira BioSciences, plans to nominate three independent directors at the 2026 annual meeting. They urge the Board to sell the company due to excessive executive compensation and spending. DOMA questions the Board’s fiduciary oversight. (50 words)

The news was first published on TheFly, a reliable source for real-time financial news. (14 words)

For more information on PCRX, check out the top stocks recommended by analysts. (15 words)

Read more about PCRX and find Disclaimer & Disclosure information. (14 words)

Read more at Yahoo Finance: DOMA intends to nominate three director candidates at Pacira annual meeting